ArticleInternational journal of molecular sciences2026
Integrating Divergence-Based Proteomic Analysis and Directed Network Diffusion to Characterize Diagnosis-Anchored Molecular Variability at the Metabolic Syndrome-Migraine Interface.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metabolic syndrome (MetS) has been associated with migraine, but the prediagnostic phase and the molecular features preceding migraine onset remain unclear. We aimed to identify a diagnosis-anchored proteomic variability window and to characterize pathways, candidate bridge proteins, and druggable targets within a direction-consistent MetS-to-migraine molecular framework. We first assessed the association between baseline MetS and incident migraine in 452,471 UK Biobank participants using Cox models. We then conducted a nested proteomics case-control analysis stratified by MetS status and applied single-sample Jensen-Shannon divergence (sJSD), network proximity, directed diffusion, and drug-target proximity analyses. Baseline MetS was associated with a higher risk of incident migraine (hazard ratio 1.09, 95% confidence interval (CI) 1.01-1.18;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.